ARTICLE | Company News

Shire, BBG make pipeline plays

December 20, 2000 8:00 AM UTC

Both Shire (LSE:SHP; SHPGY) and British Biotech (LSE:BBG; BBIOY) made in-licensing moves on Wednesday. SHP licensed from CeNeS (LSE:CEN) a research program focused on the use of dopamine D1 agonists to treat Parkinson's disease. SHP purchased 806,000 CEN shares for 500,000 ($340,000) based on a share price of 62p, and may make an additional 500,000 equity investment based on future milestones. CEN also is eligible for milestone payments and royalties. The deal comes close on the heels of SHP's previously announced acquisition of BioChem Pharma (BCHE; TSE:BCH) for $4 billion in a move to acquire preclinical and early stage products (see BioCentury, Dec. 18). ...